首页> 中文期刊> 《中国糖尿病杂志》 >新诊断重症2型糖尿病患者两种胰岛素强化治疗临床观察

新诊断重症2型糖尿病患者两种胰岛素强化治疗临床观察

         

摘要

Objective To observe the effects of short term intensive insulin treatment in newly diagnosed and critical type 2 diabetic patients. Methods The 131 newly diagnosed type 2 diabetic patients (FPG≥ll. 1 mmol/L and/or 2 hPG 14. 0 mmol/L) were randomized into two groups: continuous subcutaneous insulin infusion (CSII) and multiple subcutaneous insulin infusion (MSII) for two weeks. The duration of treatment, the dosage of insulin, and the incidence of hypoglycemia were observed. Results Compared with the MSII group, the duration of treatment and the dosage of insulin were obviously reduced in the CSII group (P<0. 01), at the same time, the incidence of hypoglycemia was lower in the CSII group (P<0. 05). Conclusion The CSII group has a better clinical effect, shorter duration of treatment, less dosage of insulin, and less incidence of hypoglycemia for achieving the target.%目的 观察短期胰岛素强化治疗新诊断重症T2DM患者治疗效果. 方法 对131例新诊断重症(FPG≥11.1mmol/L和/或2 hPG 14.0mmol/L) T2DM患者随机分为持续皮下胰岛素输注(CSⅡ)组和多次皮下注射胰岛素(MSⅡ)组,进行胰岛素强化治疗2周,观察两组治疗达标时间、胰岛素用量及发生低血糖情况. 结果 与MSⅡ组相比较,CSⅡ组血糖达标时间明显缩短(P<0.01)、CSⅡ组胰岛素用量显著低于MSII组(P<0.01)、CSII组低血糖发生率低(P<0.05). 结论 CSⅡ较MSⅡ临床治疗效果好、血糖达标快、胰岛素用量少、低血糖发生率低.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号